Viracta Therapeutics Stock Today
| VIRX Stock | USD 0.62 0.01 1.59% |
Performance0 of 100
| Odds Of DistressOver 85
|
Viracta Therapeutics is trading at 0.62 as of the 9th of June 2024; that is -1.59 percent decrease since the beginning of the trading day. The stock's open price was 0.63. Viracta Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Viracta Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of May 2024 and ending today, the 9th of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of September 2005 | Category Healthcare | Classification Health Care |
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California. Viracta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 39.27 M outstanding shares of which 668.44 K shares are at this time shorted by private and institutional investors with about 7.3 trading days to cover. More on Viracta Therapeutics
Moving together with Viracta Stock
Moving against Viracta Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Viracta Stock Highlights
| President CEO | Mark Rothera | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Viracta Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Viracta Therapeutics' financial leverage. It provides some insight into what part of Viracta Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Viracta Therapeutics (VIRX) is traded on NASDAQ Exchange in USA. It is located in 2533 South Coast Highway 101, Cardiff, CA, United States, 92007 and employs 40 people. Viracta Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.19 M. Viracta Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 39.27 M outstanding shares of which 668.44 K shares are at this time shorted by private and institutional investors with about 7.3 trading days to cover.
Viracta Therapeutics currently holds about 83.14 M in cash with (39.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Viracta Therapeutics Probability Of Bankruptcy
Ownership AllocationViracta Therapeutics shows a total of 39.27 Million outstanding shares. Over half of Viracta Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Viracta Ownership Details
Viracta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corporation | 2024-03-31 | 65.9 K | |
| Ensign Peak Advisors Inc | 2024-03-31 | 63.4 K | |
| Northern Trust Corp | 2024-03-31 | 38.2 K | |
| United Bank (vienna, Va) | 2024-03-31 | 25.2 K | |
| Beacon Pointe Advisors, Llc | 2024-03-31 | 17.5 K | |
| Xtx Topco Ltd | 2024-03-31 | 17 K | |
| Integrys Wealth Advisors Llc | 2024-03-31 | 15 K | |
| Hoylecohen, Llc | 2024-03-31 | 14 K | |
| Trust Co Of Toledo Na | 2024-03-31 | 12.3 K | |
| Bvf Inc | 2024-03-31 | 3.6 M | |
| Vanguard Group Inc | 2024-03-31 | 1.2 M |
Viracta Therapeutics Historical Income Statement
Viracta Stock Against Markets
Viracta Therapeutics Corporate Management
| Cheryl Madsen | Senior Affairs | Profile | |
| Daniel Chevallard | COO CFO | Profile | |
| Thalia MD | CoFounder | Profile | |
| Patric MBA | Senior Strategy | Profile | |
| Ronald MD | CoFounder Consultant | Profile | |
| George Hillman | CoFounder | Profile |
Additional Tools for Viracta Stock Analysis
When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.